PA5-20980

antibody from Invitrogen Antibodies

Targeting: ZEB2 KIAA0569, SIP-1, SIP1, ZFHX1B

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-20980

Provider

Invitrogen Antibodies

Product name

ZEB2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Due to post-translational modifications, ZEB2 migrates at ~180kDa in SDS-PAGE. A suggested positive control is Jurkat cell lysate.

Concentration

1 mg/mL

References

Submitted references

Potential functions of embryonic cardiac macrophages in angiogenesis, lymphangiogenesis and extracellular matrix remodeling.

Gula G, Rumiński S, Niderla-Bielińska J, Jasińska A, Kiernozek E, Jankowska-Steifer E, Flaht-Zabost A, Ratajska A
Histochemistry and cell biology 2021 Jan;155(1):117-132

---

Activation of Notch1 signaling in podocytes by glucose-derived AGEs contributes to proteinuria.

Nishad R, Meshram P, Singh AK, Reddy GB, Pasupulati AK
BMJ open diabetes research & care 2020 Jun;8(1)

---

Growth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathy.

Nishad R, Mukhi D, Tahaseen SV, Mungamuri SK, Pasupulati AK
The Journal of biological chemistry 2019 Nov 1;294(44):16109-16122

---

ZEB2, a master regulator of the epithelial-mesenchymal transition, mediates trophoblast differentiation.

DaSilva-Arnold SC, Kuo CY, Davra V, Remache Y, Kim PCW, Fisher JP, Zamudio S, Al-Khan A, Birge RB, Illsley NP
Molecular human reproduction 2019 Feb 1;25(2):61-75

---

Mechanoresponsive stem cells acquire neural crest fate in jaw regeneration.

Ransom RC, Carter AC, Salhotra A, Leavitt T, Marecic O, Murphy MP, Lopez ML, Wei Y, Marshall CD, Shen EZ, Jones RE, Sharir A, Klein OD, Chan CKF, Wan DC, Chang HY, Longaker MT
Nature 2018 Nov;563(7732):514-521

---

DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis.

Lee E, Wang J, Yumoto K, Jung Y, Cackowski FC, Decker AM, Li Y, Franceschi RT, Pienta KJ, Taichman RS
Neoplasia (New York, N.Y.) 2016 Sep;18(9):553-66

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of Jurkat cell lysate using a ZEB2 polyclonal antibody (Product # PA5-20980) at (A) 1 and (B) 2 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western Blot analysis of ZEB2 in EL4 cell lysate with ZEB2 Polyclonal Antibody (Product # PA5-20980) at 1 µg/mL in (A) the absence and (B) the presence of blocking peptide.

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence of ZEB2 in Jurkat cells with ZEB2 Polyclonal Antibody (Product # PA5-20980) at 20 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence of ZEB2 in Jurkat cells with ZEB2 Polyclonal Antibody (Product # PA5-20980) at 20 µg/mL. Red: ZEB2 Blue: DAPI staining

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry of ZEB2 in Jurkat cells with ZEB2 Polyclonal Antibody (Product # PA5-20980) at 20 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence of ZEB2 in Jurkat cells with ZEB2 Polyclonal Antibody (Product # PA5-20980) at 20 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence of ZEB2 in Jurkat cells with ZEB2 Polyclonal Antibody (Product # PA5-20980) at 20 µg/mL. Red: ZEB2 Blue: DAPI staining

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 4 Silencing DNMT1 is correlated with EMT induction and stemness in PCa cells. PCa cells (PC3 or DU145) were transiently transfected with siRNA targeting DNMT1 and cultured for 72 hours. (A) mRNA levels of DNMT1 in control or DNMT1-silenced PCa cells (PC3 or DU145) as quantified by real-time PCR. (B) Protein levels of DNMT1 in control or DNMT1-silenced PCa cells (PC3 or DU145) as quantified by Western blots. (C) EMT markers in control or DNMT1-silenced PCa cells (PC3 or DU145) as quantified by Western blots. (D) Migration of DNMT1-silenced PCa cells was performed by chemotaxis assays. (E) CSC populations (CD133 + /CD44 + phenotype) from control or DNMT1-silenced PCa cells (PC3 or DU145) as evaluated by FACS analysis. The data in A, D, and E are representative of mean +- SD ( n = 6). P values were calculated by Student's t test. (F) Stem cell-related transcription factors in control or DNMT1-silenced PCa cells (PC3 or DU145) as quantified by Western blots. (G) PKCalpha in control or DNMT1-silenced PCa cells (PC3 or DU145) as quantified by Western blots. mRNA levels of (H) PKCalpha, (I) Zeb2, and (J) KLF4 expression in control or DNMT1-silenced PCa cells (PC3 or DU145) with the presence or absence of a pan-PKC inhibitor for 3 days as quantified by real-time PCR. The data in H, I, and J are representative of mean +- SD ( n = 3). P values were calculated by Student's t test. Figure 4